• No results found

VU Research Portal

N/A
N/A
Protected

Academic year: 2021

Share "VU Research Portal"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

VU Research Portal

Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors

Xu, G.

2016

document version

Publisher's PDF, also known as Version of record

Link to publication in VU Research Portal

citation for published version (APA)

Xu, G. (2016). Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in

BRCA1-mutated mouse mammary tumors.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain

• You may freely distribute the URL identifying the publication in the public portal ? Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

(2)

208

PHD PORTFOLIO

Name PhD student: Guotai Xu PhD period: 2009.10.13-2016.01.05

Name PhD supervisors: Prof. dr. Sven Rottenberg and Prof. dr. Piet Borst Name PhD promotors: Prof. dr. Hein te Riele and Prof. dr. Sven Rottenberg

I PhD training

Attended Courses

 Radiotherapy introduction course

 Radiation protection course

 Laboratory animal course, Utrecht, 2010

 OOA course “Noncoding RNAs and Cancer”, NKI, 2010

 Course “Next Generation Sequencing”, LUMC, 2011

 OOA course “Preclinical assays” NKI, 2012

 OOA course” Histopathology of tumors”, Vumc, January 30-31, 2013

OOA course “The Macroscopic, Microscopic and Pathologic Anatomy of the House Mouse”, AMC, April 8 - 11, 2013

 OOA course “Basic Medical Statistics”, NKI, Nov 22, November 25 -29, 2013

 OOA course “Replication stress and chromosomal instability”, NKI, AMC and VUMC, January 6-10, 2014

 MGC-OOA course “Transgenesis, gene targeting and in vivo imaging”, LUMC, June 8-12, 2015

Attended Meetings

 “AACR Translational Cancer Medicine”, Amsterdam, Mar 21-24, 2010

 “OOA PhD students retreat”, poster presentation, Texel, 2010

 “Responses to DNA damage: From Molecular mechanism to human disease”, Egmond, The Netherlands, April 3-8, 2011

 “OOA PhD students retreat”, oral presentation, Texel, 2011

 “OOA PhD students retreat”, oral presentation, Ermelo, 2012

 102 AACR annual meeting, poster presentation, Chicago, Mar 31- Apr 4, 2012

(3)

209

 “Current state-of-the-art of Proteomics in the Netherlands”, Amsterdam, Nov 30, 2012

 Keystone Symposia: Joint meeting on “DNA replication and

Recombination (X5)” and “Genomic Instability and DNA repair”, poster presentation, Banff, Canada, March 3-8, 2013

 “OOA PhD students retreat”, Zeeland, oral presentation, Oct 23 –Oct 25, 2013

 7th International PhD Student Cancer Conference, oral presentation, London Research Institute, London, June 19-21, 2013

 7th Workshop on Innovative Mouse Models, poster presentation, Leiden, The Netherlands, 2013

 International Symposium on “The promise of PARP inhibitors for Personalized Cancer Treatment”, Amsterdam, 2015

 105 AACR annual meeting, Philadelphia, Apr 18- Apr 22, 2015

II Teaching

 Bachelor student: Stephan Freriks, 2011

Project: Expression analysis of genes that may cause olaparib resistance in Brca1-/-;p53-/- mouse mammary tumors

Current position: Technician in Prof. dr. Sven Rottenberg’s group at NKI

 Master student (co-supervised with Prof. dr. Sven Rottenberg): Bharath Kumar Sampadi, 2011-2012

Project: Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance

Current position: PhD student in Leiden University

 Master student: Chenwei Hu, 2012

Project: Loss of Helb causes PARP inhibitor resistance in BRCA1; p53-deficient mouse mammary tumor cells

Referenties

GERELATEERDE DOCUMENTEN

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. PARP-1 and Ku compete

b, Quantification of RAD51 foci in KB1P-G3 cells (with or without REV7 depletion) transfected with an empty vector (GFP) or vectors containing mouse or human

We observed this phenomenon by immunofluorescence of endogenous HELB in MEFs, where HELB loses its nuclear enrichment in cells that are undergoing DNA replication (Figure 6A and

In addition, we found that XRN2 loss also causes PARP inhibitor (PARPi) resistance of Brca1; p53-deficient mouse mammary tumor cells both in vitro and in vivo.. We aim

In particular, the groups of Jos Jonkers and Andre Nussenzweig found that loss of 53BP1 enhanced end resection at DSBs and restored BRCA1- independent HR,

In Chapter 2, we report that loss of REV7 (also known as MAD2L2) in mouse and human cells rescues CTIP-dependent end resection of DSBs in BRCA1- deficient

Consistent met de nieuwe rol van HELB als antagonist van resectie, leidt verlies van HELB ook tot gedeeltelijk herstel van HR en resistentie tegen PARP remming

Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors..